Clinical trial
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
NCT06843590 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)
- Lead sponsor
- Alkermes, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 22, 2025
- Completion date
- November 30, 2026
- Enrollment
- 126 (estimated)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.